Drug Trial Radar · NCT05005975
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
286
Actual
Start
Aug 10, 2021
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Tanabe Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the long-term safety and tolerability of oral dersimelagon.
Conditions
- EPP
- XLP
Interventions
MT-7117Drug
MT-7117
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with Treatment emergent adverse events (TEAEs) (including serious adverse events [SAEs] and adverse events of special interest [AESIs]).Time frame: up to 66 further months
- Number of patients with abnormal Physical examination dataTime frame: up to 66 further months
- Number of patients with Nevi appearanceTime frame: up to 66 further months
Locations
45 sites in 15 countries. Site status is shown where the registry gives one.
Marvel Clinical Research, LLC
Huntington Beach, California
University of California at San Francisco - CSF Porphyria Center
San Francisco, California
University Of Miami School Of Medicine, Center For Liver Diseases
Miami, Florida
Massachusetts General Hospital
Boston, Massachusetts
MetroBoston Clinical Partners, LLC
Brighton, Massachusetts
Henry Ford Health System
Detroit, Michigan
Kansas City Research Institute
Kansas City, Missouri
Icahn School of Medicine at Mount Sinai (ISSMS)-The Mount Sinai Hospital (MSH)
New York, New York
Wake Forest University Baptist Health
Winston-Salem, North Carolina
Remington-Davis Clinical Research
Columbus, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
The University of Texas Medical Branch (UTMB)
Galveston, Texas
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington
Wesley Medical Research
Brisbane, Queensland, Australia
Royal Melbourne Hospital (RMH)
Parkville, Victoria, Australia
University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski
Sofia, Bulgaria
University of Alberta Hospital
Edmonton, Alberta, Canada
Institute for Clinical and Experimental Medicine - IKEM
Prague, Czechia
Centre Hospitalier Universitaire de Bordeaux - Hopital Saint - Andre
Bordeaux, France
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Louis-Mourier
Colombes, France
CHU Nantes
Nantes, France
Hospital Bichat-Hopitaux Universitaires Paris Nord Val de Seine
Paris, France
Charite - Universitaetsmedizin Berlin
Berlin, Germany
Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
Brescia BS, Italy
Azienda Sanitaria Ospedaliera Santa Croce E Carle - Cuneo
Cuneo CN, Italy
Ospedalle Galliera
Genova GE, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano
Milan, Italy
U.O.C. Medicina Interna Azienda ospedaliero Universitaria Policlinico di Modena
Modena, Italy
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Materno-Infantile - Burlo Garofolo - Clinica Pediatrica
Trieste TS, Italy
I.F.O. Hospital, Centro Porfirie e Malattie Rare
Roma, Rome, Italy
Hamamatsu University Hospital
Shizuoka, Japan
Kobe University Hospital
Kobe, Hyōgo, Japan
Sophia Dermatology Clinic
Kanazawa, Ishikawa-ken, Japan
Osaka Medical College Hospital
Takatsuki, Osaka, Japan
Tokyo Saiseikai Central Hospital
Minato-ku, Tokyo, Japan
Toyama University Hospital
Sugitani, Toyama, Japan
Erasmus MC, Universitair Medisch Centrum Rotterdam
Rotterdam, Netherlands
Haukeland University Hospital
Bergen, Norway
Instytut hematologii i Transfuzjologii
Warsaw, Poland
Hospital Clínic de Barcelona
Barcelona, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.